Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Observational × Recurrence × trametinib × Clear all

Status

Sponsor Class

Study Type

Interventional 3 Observational 1

Sponsor

Conditions

Melanoma 7 Carcinoma, Non-Small-Cell Lung 2 Thyroid Neoplasms 1 Skin Neoplasms 1 Sexual Dysfunction, Physiological 1 Recurrence 1 Eunuchism 1 Erectile Dysfunction 1

Interventions

Surgical Procedures, Operative 6 Lenalidomide 4 Liver Transplantation 3 Liquid Biopsy 3 Blood Specimen Collection 3 pomalidomide 2 gilteritinib 2 Therapeutics 2 Observation 2 Neoadjuvant Therapy 2 Mitomycin 2 Magnetic Resonance Spectroscopy 2 High-Throughput Nucleotide Sequencing 2 DNA, Mitochondrial 2 Brentuximab Vedotin 2 trametinib 1 romidepsin 1 nedaplatin 1 lenvatinib 1 fluoroazomycin arabinoside 1 exemestane 1 elotuzumab 1 dacomitinib 1 dabrafenib 1 copanlisib 1 Whole Genome Sequencing 1 Transcranial Magnetic Stimulation 1 Toremifene 1 Tegafur 1 Tamoxifen 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06262919 2025-12-30

Special Drug Use-results Surveillance of Tafinlar/Mekinist

Novartis

Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡